PF 4136309

Drug Profile

PF 4136309

Alternative Names: INCB 8761; PF-04136309; PF-4136309

Latest Information Update: 10 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Analgesics; Antineoplastics
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatic fibrosis; Pain; Pancreatic cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (PO)
  • 01 May 2018 Discontinued - Phase-I for Pancreatic cancer (In volunteers) in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top